1. Home
  2. CENX vs ACAD Comparison

CENX vs ACAD Comparison

Compare CENX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Aluminum Company

CENX

Century Aluminum Company

HOLD

Current Price

$46.22

Market Cap

4.6B

Sector

Industrials

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$24.83

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CENX
ACAD
Founded
1995
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Aluminum
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.3B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
CENX
ACAD
Price
$46.22
$24.83
Analyst Decision
Strong Buy
Buy
Analyst Count
3
22
Target Price
$65.67
$30.55
AVG Volume (30 Days)
1.9M
1.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
3.23
0.02
Revenue
$1,893,200,000.00
$726,437,000.00
Revenue This Year
$20.77
$18.80
Revenue Next Year
$14.58
$11.70
P/E Ratio
$14.35
$1,241.50
Revenue Growth
N/A
40.45
52 Week Low
$20.21
$19.69
52 Week High
$70.43
$28.35

Technical Indicators

Market Signals
Indicator
CENX
ACAD
Relative Strength Index (RSI) 46.63 51.72
Support Level $43.38 $20.56
Resistance Level $47.35 $25.36
Average True Range (ATR) 1.93 0.76
MACD 0.81 -0.26
Stochastic Oscillator 85.76 23.84

Price Performance

Historical Comparison
CENX
ACAD

About CENX Century Aluminum Company

Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: